The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Equivocal, explicit and emergent actions of PKC isoforms in cancer
Abstract
The maturing mutational landscape of cancer genomes, the development and application of clinical interventions and evolving insights into tumour-associated functions reveal unexpected features of the protein kinase C (PKC) family of serine/threonine protein kinases. These advances include recent work showing gain or loss-of-function mutations relating to driver or bystander roles, how conformational constraints and plasticity impact this class of proteins and how emergent cancer-associated properties may offer opportunities for intervention. The profound impact of the tumour microenvironment, reflected in the efficacy of immune checkpoint interventions, further prompts to incorporate PKC family actions and interventions in this ecosystem, informed by insights into the control of stromal and immune cell functions. Drugging PKC isoforms has offered much promise, but when and how is not obvious.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Another activator of PKC, tigilanol tiglate, has been approved for use in canine mast cell tumors [129].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Meyer, T., Regenass, U., Fabbro, D., Alteri, E., Röusel, J., Möller, M., Caravatti, G., & Matter, A. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430519 · Cited by 407
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
The role of protein kinase C in cell surface signal transduction and tumour promotion
Nishizuka, Y. (1984) · Nature · doi:10.1038/308693a0 · Cited by 7,454
Castagna, M., Takai, Y., Kaibuchi, K., Sano, K., Kikkawa, U., & Nishizuka, Y. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34459-4 · Cited by 4,725
Thastrup, O., Cullen, P. J., Drøbak, B. K., Hanley, M. R., & Dawson, A. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2466 · Cited by 3,270
The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., & Loriolle, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98476-0 · Cited by 2,456
Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinase
Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., & Tomita, F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90008-2 · Cited by 2,452
Shimoyama, M., & members of The Lymphoma Study Group (1984–87) (1991) · British Journal of Haematology · doi:10.1111/j.1365-2141.1991.tb08051.x · Cited by 1,608
The extended protein kinase C superfamily
MELLOR, H., & PARKER, P. J. (1998) · Biochemical Journal · doi:10.1042/bj3320281 · Cited by 1,538
Self-citation
Research works printed but not linked: 1
- Linch, M. Protein Kinase Cι in Mammalian Cell Polarity and Cancer. PhD thesis, Univ. College London (2012).
Cited by
T cell receptor (TCR) signaling in health and disease
Shah, K., Al-Haidari, A., Sun, J., & Kazi, J. U. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00823-w · Cited by 604
PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis
Zhang, H.-L., Hu, B.-X., Li, Z.-L., Du, T., Shan, J.-L., Ye, Z.-P., Peng, X.-D., Li, X., Huang, Y., Zhu, X.-Y., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-021-00818-3 · Cited by 582
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Another activator of PKC, tigilanol tiglate, has been approved for use in canine mast cell tumors [129].”
BackgroundSerine signaling governs metabolic homeostasis and health
He, L., Ding, Y., Zhou, X., Li, T., & Yin, Y. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.03.001 · Cited by 106
Overarching roles of diacylglycerol signaling in cancer development and antitumor immunity
Cooke, M., & Kazanietz, M. G. (2022) · Science Signaling · doi:10.1126/scisignal.abo0264 · Cited by 103
“Although conferring growth advantage through the ERK pathway (126–128), the glioma mutant PKCD463H displays impaired catalytic potential and reduced ability to localize at the plasma membrane [the mechanistic interpretations of which are reviewed elsewhere (11)].”
BackgroundInfluential
Metadata
- Authors
- Parker, P. J., Brown, S. J., Calleja, V., Chakravarty, P., Cobbaut, M., Linch, M., Marshall, J. J. T., Martini, S., McDonald, N. Q., Soliman, T., & Watson, L.
- Affiliations
- King's College London (GB)
- The Francis Crick Institute (GB)
- University College London (GB)
- Barts Cancer Institute (GB)
- Corresponding author
- Parker, Peter J.
- ORCID
- Venue
- Nature Reviews Cancer
- Published
- 2020-11-11
- Volume
- 21
- Issue
- 1
- Pages
- 51-63
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W3100551133
- Cited by
- 65
- References
- 191
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 10 · 2023: 14 · 2022: 12 · 2021: 7
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- BIROn (Birkbeck, University of London) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Wellcome Trust (FC001130)
- Francis Crick Institute (10002, 10130, 10115)
- Barts Charity (MGU0460)
- Cancer Research UK (FC001130)
- National Institute for Health and Care Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- PKC isoforms, cancer, conformational plasticity, tumor microenvironment, immune checkpoint, stromal cells, immune cells, PKC inhibitors, tumor suppression, tumor promotion, target validation
- MeSH terms
- Animals, Humans, Isoenzymes, Mutation, Neoplasms, Phosphorylation, Promoter Regions, Genetic, Protein Kinase C, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Equivocal, explicit and emergent actions of PKC isoforms in cancer. https://app.cochat.ai/papers/10.1038/s41568-020-00310-4
- The paper
- Parker, P. J., Brown, S. J., Calleja, V., Chakravarty, P., Cobbaut, M., Linch, M., Marshall, J. J. T., Martini, S., McDonald, N. Q., Soliman, T., & Watson, L. (2021). Equivocal, explicit and emergent actions of PKC isoforms in cancer. Nature Reviews Cancer. https://doi.org/10.1038/s41568-020-00310-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.